NASDAQ:MNOV MediciNova (MNOV) Stock Price, News & Analysis → The ONE AI sSock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free MNOV Stock Alerts $1.35 +0.05 (+3.85%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.31▼$1.4250-Day Range$1.28▼$1.5352-Week Range$1.26▼$2.66Volume37,211 shsAverage Volume42,911 shsMarket Capitalization$66.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get MediciNova alerts: Email Address Ad Weiss RatingsThe ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About MediciNova Stock (NASDAQ:MNOV)MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Read More MNOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNOV Stock News HeadlinesMarch 12, 2024 | globenewswire.comMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of ToxicologyMarch 12, 2024 | americanbankingnews.comStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)March 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 29, 2024 | finance.yahoo.comMNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…February 28, 2024 | money.usnews.comMedicinova IncJanuary 17, 2024 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaJanuary 17, 2024 | finance.yahoo.comMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaDecember 21, 2023 | finance.yahoo.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of ToxicologyMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.December 6, 2023 | markets.businessinsider.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeDecember 6, 2023 | finance.yahoo.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeNovember 27, 2023 | finance.yahoo.comMNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…November 22, 2023 | finance.yahoo.comThe past five years for MediciNova (NASDAQ:MNOV) investors has not been profitableNovember 20, 2023 | msn.comWhy Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?November 19, 2023 | finance.yahoo.comMediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-OncologyOctober 28, 2023 | benzinga.comMediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 27, 2023 | finance.yahoo.comMediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of PhenylketonuriaOctober 12, 2023 | finance.yahoo.comWe're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash WiselyOctober 10, 2023 | finance.yahoo.comMediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in CanadaOctober 5, 2023 | finanznachrichten.deMediciNova, Inc.: MediciNova Receives Gene Therapy Milestone PaymentOctober 4, 2023 | finance.yahoo.comMediciNova Receives Gene Therapy Milestone PaymentSeptember 29, 2023 | finance.yahoo.comMNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model…September 28, 2023 | msn.comMediciNova gains after nonclinical data for lead asset in lung injurySeptember 27, 2023 | finance.yahoo.comMediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung InjuryAugust 21, 2023 | finance.yahoo.comMNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury…August 17, 2023 | finance.yahoo.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-OncologyAugust 16, 2023 | benzinga.comMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in EuropeSee More Headlines Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today3/19/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees13Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net MarginsN/A Pretax Margin-856.80% Return on Equity-13.19% Return on Assets-12.50% Debt Debt-to-Equity RatioN/A Current Ratio15.61 Quick Ratio15.61 Sales & Book Value Annual Sales$1 million Price / Sales66.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book1.06Miscellaneous Outstanding Shares49,050,000Free Float40,757,000Market Cap$66.22 million OptionableOptionable Beta0.73 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Yuichi Iwaki M.D. (Age 74)Ph.D., Co-Founder, President, CEO & Executive Director Comp: $933.05kDr. Kazuko Matsuda M.D. (Age 58)M.P.H., Ph.D., Chief Medical Officer & Director Comp: $653.65kDr. David H. Crean M.B.A. (Age 59)Ph.D., Chief Business Officer Mr. John O'Neil CPAControllerKey CompetitorsKezar Life SciencesNASDAQ:KZREliem TherapeuticsNASDAQ:ELYMAssembly BiosciencesNASDAQ:ASMBInflaRxNASDAQ:IFRXConnect BiopharmaNASDAQ:CNTBView All CompetitorsInstitutional OwnershipBarclays PLCSold 12,500 shares on 2/15/2024Ownership: 0.186%Bank Julius Baer & Co. Ltd ZurichBought 19,000 shares on 2/2/2024Ownership: 0.039%Simplex Trading LLCBought 700 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions MNOV Stock Analysis - Frequently Asked Questions How have MNOV shares performed in 2024? MediciNova's stock was trading at $1.50 on January 1st, 2024. Since then, MNOV stock has decreased by 10.0% and is now trading at $1.35. View the best growth stocks for 2024 here. Are investors shorting MediciNova? MediciNova saw a increase in short interest in February. As of February 29th, there was short interest totaling 337,800 shares, an increase of 34.5% from the February 14th total of 251,200 shares. Based on an average daily volume of 58,900 shares, the short-interest ratio is presently 5.7 days. Approximately 0.7% of the company's stock are sold short. View MediciNova's Short Interest. When is MediciNova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MNOV earnings forecast. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.04. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY). Who are MediciNova's major shareholders? MediciNova's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Barclays PLC (0.19%), Bank Julius Baer & Co. Ltd Zurich (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MNOV) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe world’s greatest investmentPorter & CompanyBiden out June 13?Paradigm PressMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.